Citadel Advisors
IMMX icon

Citadel Advisors’s Immix Biopharma IMMX Stock Holding History

Citadel Advisors’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,500
Closed -$25.3K – 14990
2024
Q4 		$25.3K Buy
11,500
+2,600
+29% +$4.75K ﹤0.01% 13021
2024
Q3 		$13.3K Buy
+8,900
New +$17.9K ﹤0.01% 13068

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Citadel Advisors's IMMX Position: Q1 2026 in Review

Citadel Advisors reduced its Immix Biopharma (IMMX) stake by 37% in Q1 2026, selling an estimated $207K and leaving 47,173 shares worth $430K. The position accounts for ﹤0.01% of the portfolio, ranked #9665.

Citadel Advisors first reported a position in IMMX in Q4 2021 and has held it in 5 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Citadel Advisors held 47,173 shares of Immix Biopharma worth $430K as of Q1 2026.
  • Citadel Advisors sold 28,165 Immix Biopharma shares in Q1 2026, an estimated $207K.
  • Immix Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9665 holding.
  • Citadel Advisors first reported a position in Immix Biopharma in Q4 2021 and has held it in 5 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.